Nordic Nanovector ASA - Issuance of PSUs

Monday, April 23, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

OSLO, Norway, April 23, 2018 /PRNewswire/ --

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector"

or the "Company") has on 23 April 2018 resolved to grant 15 000 Performance Share Units ("PSUs") to new employees under the Company's new equity incentive plan that was approved at the Company's extraordinary general meeting
on 20 December 2017 (the "EGM"). In accordance with the resolution at the EGM the PSUs are secured by a corresponding number of free-standing warrants. The sole purpose of the free-standing warrants is to ensure delivery of shares in the Company upon exercise of the PSUs. The free-standing warrants do not give the PSU holder a right to subscribe for any additional shares in the Company. For further information about the PSUs and the related warrants, see appendix 3 to the notice to the EGM.

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to a duty of disclosure pursuant to Section 3.2 of the continuing obligations for listed companies.

CONTACT:

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44-7561-431-762

Email: ir@nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---issuance-of-psus,c2503191

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa---issuance-of-psus-300634583.html

SOURCE Nordic Nanovector

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store